Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Elise Puffer

Nurse Practitioner Louisville, KY Nurse Practitioner

NPI 1528316742 CMS profile 10748867

100 Mallard Creek Rd Ste 320, Louisville, KY 40207

Open in the dashboard

General payments

$1,475

33 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elise Puffer of Louisville, KY is reported in the CMS Open Payments database as having received $1,475 across 33 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $239 2
2024 General $17 1
2023 General $249 4
2022 General $726 23
2021 General $243 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elise Puffer
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Elise Puffer were reported at $239. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Elise Puffer Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $243 $135 $40–$426 $132
2022 $726 $152 $48–$470 $149
2023 $249 $166 $54–$529 $160
2024 $17 $173 $55–$556 $164
2025 $239 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Biohaven Pharmaceutical Holding Company Ltd. $460 18 payments
  2. Biohaven Pharmaceuticals, Inc. $243 3 payments
  3. Esperion Therapeutics, Inc. $121 1 payment
  4. Phathom Pharmaceuticals, Inc. $120 1 payment
  5. Alnylam Pharmaceuticals Inc. $120 1 payment
  6. Novo Nordisk Inc $112 1 payment
  7. Agile Therapeutics, Inc. $106 1 payment
  8. Exact Sciences Corporation $101 1 payment
  9. Amarin Pharma Inc. $76 5 payments
  10. Organon LLC $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,475 33 payments
Products named General payments · program years 2021–2025
  1. NURTEC ODT $703 21 payments
  2. NEXLETOL $121 1 payment
  3. NEXLIZET $121 1 payment
  4. GIVLAARI $120 1 payment
  5. VOQUEZNA $120 1 payment
  6. Wegovy $112 1 payment
  7. Twirla $106 1 payment
  8. Cologuard Collection Kit $101 1 payment
  9. Vascepa $76 5 payments
  10. NEXPLANON $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 109 drugs

Part D claims

4,885

Median for Nurse Practitioner: 389

Drug cost

$318,079

Median for Nurse Practitioner: $21,885

Branded share of claims

17.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 35 $43,723
Eliquis Apixaban Brand 31 $39,332
Jardiance Empagliflozin Brand 26 $29,789
Vascepa Icosapent Ethyl Brand 38 $22,796
Repatha Sureclick Evolocumab Brand 25 $21,181
Linzess Linaclotide Brand 14 $19,495
Januvia Sitagliptin Phosphate Brand 13 $17,437
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 23 $16,967
Xarelto Rivaroxaban Brand 18 $15,233
Myrbetriq Mirabegron Brand 11 $12,569

The 10 drugs with the highest cost, of 109 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$83,270

Of which drugs: $8,879

Medicare patients

243

Average age 73

Services billed

1,716

171 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 44%
Diabetes 27%
Ischemic heart disease 24%
Depression 19%
Atrial fibrillation 17%
Chronic kidney disease 16%
COPD 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 57 59 $4,728
Pcv20 vaccine im 90677 Office 12 12 $3,450

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

33 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record